I ka hoʻomaka ʻana o Malaki, ua ʻāpono ka National Medical Products Administration iā Jaypirca® (pirtobrutinib) no ka mālama ʻana i nā poʻe maʻi makua me ka leukemia lymphocytic mau loa (CLL) a i ʻole ka lymphoma lymphocytic liʻiliʻi (SLL) i loaʻa i ka liʻiliʻi o hoʻokahi lāʻau lapaʻau systemic ma mua, me kahi mea hoʻopaʻa tyrosine kinase (BTK) a Bruton.
He mea hoʻopaʻa kinase koho kiʻekiʻe ʻo Pirtobrutinib e hoʻohana ana i kahi ʻano hana hoʻopaʻa non-covalent hou e hoʻonui i ka pono o ke kuhikuhi ʻana i ke ala BTK i nā poʻe maʻi CLL/SLL i mālama mua ʻia me kahi mea hoʻopaʻa BTK covalent (ibrutinib, acalabrutinib, a i ʻole zanubrutinib). Ua loaʻa iā Pirtobrutinib ka ʻae ʻia mai ka US FDA i Ianuali 2023 ma ke ʻano he mea hoʻopaʻa BTK non covalent (reversible). I ʻOkakopa 2024, ua ʻae ʻia ʻo pirtobrutinib ma Kina ma ke ʻano he monotherapy no ka mālama ʻana i nā poʻe maʻi makua me ka relapsed a i ʻole refractory mantle cell lymphoma (MCL) i loaʻa mua ma ka liʻiliʻi ʻelua mau ʻano lapaʻau systemic mua, me kahi mea hoʻopaʻa tyrosine kinase (BTK) a Bruton.
ʻO ka ʻae ʻia ʻana o kēia hōʻailona hou e pili ana i nā hopena mai ka noiʻi honua, multicenter, randomized, Phase 3 BRUIN CLL 321. ʻO BRUIN CLL 321 ka hoʻokolohua Phase 3 randomized mua loa o ka honua i mālama ʻia i nā poʻe maʻi me CLL/SLL i mālama mua ʻia me kahi covalent BTK inhibitor (cBTKi). Ua hoʻopaʻa inoa ke aʻo ʻana i ka huina o 238 mau maʻi a loiloi i ka pono a me ka palekana o ka pirtobrutinib monotherapy versus ke koho a ka mea noiʻi o IdelaR (idelalisib plus rituximab) a i ʻole BR (bendamustine plus rituximab). Ua hōʻike nā hopena ua hoʻolōʻihi nui ka pirtobrutinib i ka median progression free survival (PFS) i hoʻohālikelike ʻia me ka regimen koho a ka mea noiʻi (14.0 mahina vs 8.7 mahina; hazard ratio [HR] = 0.54). Eia kekahi, ʻoi aku ka haʻahaʻa o ka nui o ka hoʻopau ʻana ma muli o nā hanana maikaʻi ʻole e pili ana i ka lāʻau me ka pirtobrutinib (5.2% vs 21.1%), e kākoʻo hou ana i kona pono a me nā pono hoʻomanawanui i nā poʻe maʻi i mālama mua ʻia me kahi mea hoʻopaʻa BTK covalent.
E Kāhea iā Mākou e Hoʻomaka i kāu Huakaʻi o ka Manaʻolana
Ua hoʻolaʻa ʻia ka ʻOihana Honua o ka Halemai Oncology Hema o Beijing no ka hāʻawi ʻana i nā poʻe maʻi honua me ke komo ʻana i nā lāʻau lapaʻau kanesa holomua loa. Inā ʻoe a i ʻole kekahi lālā o ka ʻohana e kū nei i kahi maʻi kanesa a ua loaʻa iā ʻoe kahi pane kūpono ʻole i nā lāʻau lapaʻau maʻamau, ua mākaukau kā mākou hui International Patient Services e hāʻawi iā ʻoe i ka ʻike kikoʻī a me nā hoʻolālā lapaʻau pilikino.
E ʻoluʻolu e hoʻokaʻaʻike mai iā mākou ma o kēia mau ala e aʻo hou ai e pili ana i nā koho lapaʻau maʻi kanesa:
- Kelepona: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Ke kakali nei ka ʻOihana Honua o ka Halemai Oncology Hema o Beijing i ka hui pū ʻana me ʻoe i ke kaua ʻana i ka maʻi kanesa. Ma hea ʻoe ma ka honua, ua kūpaʻa mākou i ka hāʻawi ʻana iā ʻoe i ke kākoʻo lapaʻau ʻoihana loa a me ka mālama aloha.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Ka manawa hoʻouna: Malaki-12-2026